Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients With Prostate Cancer

NCT04089553 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04089553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04089553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients With Prostate Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 29, 2019
Completion date
April 11, 2023
Enrollment
59 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer (mcrpc), prostate cancer